Raajit K. Rampal, MD, PhD

home / authors / raajit-k-rampal-md-phd

Raajit Rampal, MD, is director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center

Articles

Raajit K. Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center

Dr. Rampal on Tools to Estimate Prognosis in Myelofibrosis

Raajit K. Rampal, MD, PhD
October 13th 2020

Raajit K. Rampal, MD, PhD, discusses available tools to estimate prognosis in myelofibrosis.

Read More

Dr. Rampal on Challenges With Targeting High-Risk Mutations in Myelofibrosis

Dr. Rampal on Challenges With Targeting High-Risk Mutations in Myelofibrosis

Raajit K. Rampal, MD, PhD
September 28th 2020

Raajit K. Rampal, MD, PhD, discusses challenges with targeting high-risk mutations in patients with myelofibrosis.

Read More

Dr. Rampal on the Evolving Understanding of Genomic Alterations in MPNs

Dr. Rampal on the Evolving Understanding of Genomic Alterations in MPNs

Raajit K. Rampal, MD, PhD
September 24th 2020

Raajit K. Rampal, MD, PhD, discusses the evolving understanding of genetic alterations in myeloproliferative neoplasms.

Read More

Dr. Rampal on Investigational Agents in MPNs

Dr. Rampal on Investigational Agents in MPNs

Raajit K. Rampal, MD, PhD
February 22nd 2020

Raajit K. Rampal, MD, PhD, discusses investigational agents in myeloproliferative neoplasms.

Read More

Dr. Rampal on Ongoing Research With Pacritinib in Myelofibrosis

Dr. Rampal on Ongoing Research With Pacritinib in Myelofibrosis

Raajit K. Rampal, MD, PhD
January 24th 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing research with pacritinib in myelofibrosis.

Read More

Dr. Rampal on Unmet Needs in Myelofibrosis and Polycythemia Vera

Dr. Rampal on Unmet Needs in Myelofibrosis and Polycythemia Vera

Raajit K. Rampal, MD, PhD
January 15th 2020

Raajit K. Rampal, MD, PhD, discusses unmet needs in the treatment of patients with myelofibrosis and polycythemia vera.

Read More

Dr. Rampal on Treatment Options in Polycythemia Vera

Dr. Rampal on Treatment Options in Polycythemia Vera

Raajit K. Rampal, MD, PhD
January 8th 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in polycythemia vera.

Read More

<123

Latest Updated Articles

Alexis LeVee, MD
Published: May 14th 2025 | Updated: May 30th 2025
Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting
Arielle Heeke, MD
Published: May 2nd 2025 | Updated: May 6th 2025
Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer